Introduction {#section1-2042018820911803}
============

Type 1 and type 2 diabetes are characterized by elevated plasma glucose levels and increased cardiovascular mortality.^[@bibr1-2042018820911803]^ Since the UK Prospective Diabetes Study (UKPDS) was published in 1998, it has been recognised that intensive glycaemic control reduces the risk of microvascular disease in patients with newly diagnosed type 2 diabetes.^[@bibr2-2042018820911803]^ Moreover, the 10-year follow up demonstrated a significant reduction in myocardial infarction and cardiovascular mortality in patients receiving intensive therapy.^[@bibr3-2042018820911803]^ Nevertheless, in several subsequent trials exploring the effect of intensive glycaemic control *versus* less intensive glycaemic control, intensive glucose-lowering therapy failed to reduce the risk of cardiovascular disease and cardiovascular mortality ([Table 1](#table1-2042018820911803){ref-type="table"}). Notably, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, intensive glycaemic control resulted in a significant increase in all-cause mortality, driven mainly by a 35% increase in cardiovascular mortality compared with patients on standard therapy, which led to an early discontinuation of the trial.^[@bibr4-2042018820911803]^ Both groups in the ACCORD trial were treated with insulin, sulphonylureas, metformin and thiazolidinediones. Since the ACCORD trial was discontinued, two new classes of glucose-lowering drugs have been shown to have beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes in large-scale cardiovascular outcome trials.^[@bibr5-2042018820911803],[@bibr6-2042018820911803]^ Interestingly, the beneficial effects on cardiovascular disease seem to be independent of HbA~1c~ reductions, and the cardiovascular effect of intensive glucose-lowering therapy is still a subject of some controversy. Importantly, patients randomized to intensive glycaemic control in the ACCORD trial had a threefold increase in incidence of severe hypoglycaemia, and it has been hypothesized that the marked increase in incidence of hypoglycaemia may account for some of the observed increase in cardiovascular mortality.^[@bibr4-2042018820911803]^ However, it has also been argued that the association between hypoglycaemia and cardiovascular disease may be explained largely by an increased vulnerability in patients experiencing hypoglycaemia.^[@bibr7-2042018820911803]^ Nevertheless, in a meta-analysis of retrospective and prospective cohort studies in patients with type 2 diabetes, severe hypoglycaemia was found to double the risk of cardiovascular disease, which could not be explained entirely by differences in comorbidities.^[@bibr8-2042018820911803]^

###### 

Large-scale clinical trials comparing intensive glucose-lowering therapy with standard therapy.

![](10.1177_2042018820911803-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                  Population                                                                                             Design                                                                                                                             Hypoglycaemia                                                                                CVD                                                                                                     All-cause mortality
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  **DCCT/EDIC** ^[@bibr9-2042018820911803],[@bibr10-2042018820911803]^   Patients with T1D aged 13--39 years (*N* = 1441)                                                       Conventional treatment with 1--2 daily insulin injections *versus* intensive treatment with ⩾3 daily injections or insulin pump\   Threefold increase in severe hypoglycaemia in the intensive treatment group (*p* \< 0.001)   No difference after the initial 6.5 years of follow-up.\                                                No difference between groups
                                                                                                                                                                                Mean follow up of 6.5 years                                                                                                                                                                                                     57% reduction in in MACE (*p* = 0.02) after median follow up of 17 years                                

  **UKPDS3** ^[@bibr11-2042018820911803],[@bibr12-2042018820911803]^     Patients with newly diagnosed T2D (*N* = 4209)                                                         Intensive treatment (metformin and SU/insulin) *versus* conventional therapy (primarily diet)\                                     Two-fold increase in severe hypoglycaemia in the intensive treatment group (*p* \< 0.0001)   No difference after the initial 10-years of follow up\                                                  No difference for Insulin/SU group\
                                                                                                                                                                                Median follow up of 10 years                                                                                                                                                                                                    Significant reductions in both SU/insulin and metformin group after 10 years of post-trial follow up\   36% reduction in the obese metformin group (*p* = 0.01)\
                                                                                                                                                                                                                                                                                                                                                                                                                MI\                                                                                                     13% (*p* = 0.007) and 17% (*p* = 0.002) reduction after 10 years of post-trial follow up
                                                                                                                                                                                                                                                                                                                                                                                                                SU/insulin: RR 0.85 (*p* = 0.01)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                Metformin: RR 0.67 (*p* = 0.005)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                Stroke\                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                SU/insulin: RR 0.91 (*p* = 0.39)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                Metformin: RR 0.80 (*p* = 0.35)                                                                         

  **ACCORD** ^[@bibr4-2042018820911803]^                                 Patients with T2D and established CVD (35%) or high CV risk (*N* = 10,251)                             Intensive glycaemic control (HbA~1c~\<6.0%) *versus* standard therapy (HbA~1c~ 7.0--7.9%)\                                         Percentage of patients experiencing at least one episode of severe hypoglycaemia\            MACE\                                                                                                   HR 1.22 (*p* = 0.04)\
                                                                                                                                                                                All glucose-lowering therapies allowed.\                                                                                           16.2 *versus* 5.1% (*p* \< 0.001), respectively                                              HR 0.90 (*p* = 0.16)\                                                                                   All-cause mortality normalized after a mean of 7.7 years of follow up\
                                                                                                                                                                                Discontinued after a mean follow up of 3.5 years                                                                                                                                                                                CV mortality\                                                                                           HR 1.01 (*p* = 0.91)
                                                                                                                                                                                                                                                                                                                                                                                                                HR 1.35 (*p* = 0.02)\                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                Nonfatal MI\                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                HR 0.76 (*p* = 0.004)\                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                Nonfatal stroke\                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                HR 1.06 (*p* = 0.74)\                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                CV mortality remained significantly increased after a mean 7.7 years of follow up\                      
                                                                                                                                                                                                                                                                                                                                                                                                                HR 1.20 (*p* = 0.02)                                                                                    

  **ADVANCE** ^[@bibr13-2042018820911803],[@bibr14-2042018820911803]^    Patients with T2D and microvascular or macrovascular complication or ⩾ 1 risk factors (*N* = 11,140)   Intensive treatment (HbA~1c~\<6.5%) *versus* standard treatment.\                                                                  Significant increase in severe hypoglycaemia in the intensive treatment group\               MACE\                                                                                                   HR 0.93 (*p* = 0.28)\
                                                                                                                                                                                Median follow up of 5 years                                                                                                        HR 1.86 (*p* \< 0.001)                                                                       HR 0.94 (*p* = 0.37)\                                                                                   No effect observed after 5.4 years of post-trial follow up
                                                                                                                                                                                                                                                                                                                                                                                                                CV mortality\                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                HR 0.88 (*p* = NS)\                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                Nonfatal MI\                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                HR 1.02 (*p* = NS)\                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                Nonfatal stroke\                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                HR 0.98 (*p* = NS)\                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                No effect observed after 5.4 years of post-trial follow up                                              

  **VADT** ^[@bibr15-2042018820911803],[@bibr16-2042018820911803]^       Patients with T2D treated with insulin or maximal-dose oral agent (*N* = 1791)                         Intensive treatment (HbA~1c~\<6.0%) *versus* standard therapy.\                                                                    Significant increase in hypoglycaemia in the intensive treatment group (*p* \< 0.001)        No difference in the primary composite CV endpoint\                                                     HR 1.07 (*p* = 0.62)\
                                                                                                                                                                                Median follow up of 5.6 years                                                                                                                                                                                                   HR 0.88 (*p* = 0.14)\                                                                                   No reduction after 9.8 years of follow up\
                                                                                                                                                                                                                                                                                                                                                                                                                Significant reduction in the primary composite CV endpoint after 9.8 years of follow up\                HR 1.05 (*p* = 0.54)
                                                                                                                                                                                                                                                                                                                                                                                                                HR 0.83 (*p* = 0.04)                                                                                    

  **ORIGIN** ^[@bibr17-2042018820911803]^                                Patients with IFG, IGT or T2D and CV risk factors (*N* = 12,537)                                       Early treatment with insulin glargine (target FPG 5.3 mmol/l) *versus* standard care.\                                             Threefold increase in severe hypoglycaemia (*p* \< 0.001)                                    MACE\                                                                                                   HR 0.98 (*p* = 0.70)
                                                                                                                                                                                Median follow up of 6.2 years                                                                                                                                                                                                   HR 1.03 (*p* = 0.63)\                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                CV death\                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                HR 1.00 (*p* = 0.98)                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CV, cardiovascular; CVD, cardiovascular disease; FPG, fasting plasma glucose; HbA~1c~, glycated haemoglobin; HR, hazard ratio; IFG, impaired fasting glucose; IGT impaired glucose tolerance; MACE, major adverse cardiovascular event (composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke); MI, myocardial infarction; NS, nonsignificant; RR, relative risk; SU, sulphonylurea; T1D, type 1 diabetes; T2D, type 2 diabetes.

A potential mechanism by which hypoglycaemia may increase cardiovascular mortality in patients with diabetes is through induction of fatal cardiac arrhythmias. Since a case series of unexplained deaths among patients with type 1 diabetes (most of whom had gone to bed in apparently good health and been found dead in the morning) was published 1991, insulin-induced hypoglycaemia has been associated with sudden overnight death in patients with type 1 diabetes, the so-called 'dead-in-bed syndrome'.^[@bibr18-2042018820911803]^ Epidemiological data have shown that sudden unexplained death may be increased 10-fold in type 1 diabetes compared with individuals without diabetes.^[@bibr19-2042018820911803]^ However, since cardiac arrhythmias are relatively rare and may be clinically asymptomatic, it has proved difficult to demonstrate a direct causal relationship. The present review aims to describe potential mechanisms by which hypoglycaemia may induce cardiac arrhythmias and provide an overview of the current available data linking hypoglycaemia to cardiac arrhythmias in patients with diabetes.

Preclinical studies {#section2-2042018820911803}
-------------------

The full pathway from hypoglycaemia to fatal cardiac arrhythmia has been explored in preclinical studies in rats. During a hyperinsulinaemic hypoglycaemic clamp targeting a plasma glucose of 0.6--0.8 mmol/l, a typical pattern of electrocardiographic abnormalities was observed ([Figure 1](#fig1-2042018820911803){ref-type="fig"}).^[@bibr20-2042018820911803]^ Initial changes consisted of prolongation of corrected QT (QTc) interval, which was followed by an increasing number of premature atrial and ventricular contractions and first-degree atrioventricular (AV) block. This was followed occasionally by nonsustained ventricular tachycardia before evolving to high-grade second-degree AV block and third-degree AV block. Before going into cardiorespiratory arrest, a lower-voltage electrocardiogram (ECG) with a markedly reduced frequency was noted. Interestingly, when cerebral glucose levels were maintained at basal levels through an intracerebroventricular glucose infusion, the adrenergic response during hypoglycaemia was blunted markedly, and incidence of cardiac arrhythmias and mortality reduced significantly. Similarly, the intravenous infusion of either alpha/beta-blockers or beta-blockers completely prevented death during hypoglycaemia (*p* = 0.029) and intravenous supplementation of plasma potassium tended to reduce mortality (*p* \< 0.08). These findings indicate that cardiac arrhythmias during insulin-induced hypoglycaemia are mediated through central activation of the sympathetic nervous system, which results in direct stimulation of the heart as well as an indirect effects through a marked increase in plasma catecholamines. The role of reductions in plasma potassium is less clear.^[@bibr20-2042018820911803]^

![Pattern of electrocardiographic changes during insulin-induced severe hypoglycaemia in a rat model as described by Reno and colleagues.^[@bibr20-2042018820911803]^\
QTc, corrected QT interval.](10.1177_2042018820911803-fig1){#fig1-2042018820911803}

In a diabetic rodent model with streptozotocin-treated diabetic rats, insulin-deficiency more than doubled the risk of third-degree AV block and death during severe hypoglycaemia compared with nondiabetic rats.^[@bibr21-2042018820911803]^ However, exposure of streptozotocin-treated rats to antecedent moderate hypoglycaemia the days before being exposed to hypoglycaemia resulted in reduced sympatoadrenergic response during severe hypoglycaemia and a significant reduction in third-degree AV block and mortality compared with nondiabetic rats.^[@bibr21-2042018820911803]^ Hence, while diabetes might increase the risk of fatal cardiac arrhythmias during severe hypoglycaemia, antecedent hypoglycaemia blunts the sympatoadrenergic response to hypoglycaemia, which might serve as a mediator of cardiac arrhythmias during severe hypoglycaemia.^[@bibr21-2042018820911803]^

Although the abovementioned findings point towards a central role for catecholamines and the sympathetic nervous system in cardiac arrhythmias during severe hypoglycaemia, they have recently been contradicted by a study from the same group.^[@bibr22-2042018820911803]^ When performing hyperinsulinaemic hypoglycaemic clamps in nondiabetic rats, neither adrenal demedullation nor chemical sympathectomy reduced the incidence of cardiac arrhythmias or death or prevented QTc prolongation. On the contrary, left-side vagotomy led to a seven-fold decrease in mortality, a four-fold reduction in first- and second-degree AV block and a complete absence of third-degree AV block. Likewise, pharmacological blockade of nicotinic receptors completely prevented death and nearly prevented any arrhythmia. These findings indicate a strong role for the parasympathetic nervous systems as a mediator of cardiac arrhythmias during hypoglycaemic conditions.^[@bibr22-2042018820911803]^

Experimentally induced hypoglycaemia in clinical studies {#section3-2042018820911803}
--------------------------------------------------------

The electrocardiographic changes in humans during hypoglycaemia have been explored in several studies employing experimental, insulin-induced hypoglycaemia.^[@bibr23-2042018820911803][@bibr24-2042018820911803][@bibr25-2042018820911803][@bibr26-2042018820911803][@bibr27-2042018820911803][@bibr28-2042018820911803][@bibr29-2042018820911803][@bibr30-2042018820911803][@bibr31-2042018820911803][@bibr32-2042018820911803]--[@bibr33-2042018820911803]^ In studies applying the hyperinsulinaemic hypoglycaemic clamp, QTc interval prolongation is an almost consistent finding in patients with type 1 diabetes and type 2 diabetes, respectively, as well as healthy control subjects.^[@bibr23-2042018820911803][@bibr24-2042018820911803][@bibr25-2042018820911803][@bibr26-2042018820911803][@bibr27-2042018820911803][@bibr28-2042018820911803][@bibr29-2042018820911803][@bibr30-2042018820911803]--[@bibr31-2042018820911803]^ QTc interval has previously been demonstrated to be a predictor of cardiovascular mortality and all-cause mortality in patients with diabetes^[@bibr34-2042018820911803],[@bibr35-2042018820911803]^ and QTc interval prolongation increases the risk of developing ventricular arrhythmias.^[@bibr36-2042018820911803]^ However, the magnitude of QTc interval prolongation during experimental hypoglycaemia varies with the applied method of correcting for heart rate. Multiple methods for heart rate correction have been developed, and, while Bazett's correction is most widely used, it is generally recognized to overcorrect when the heart rate is in the high range, whereas Fridericia's correction remains reliable in the high range.^[@bibr37-2042018820911803]^ Indeed, in one study, a significant change in QTc interval during hypoglycaemia compared with baseline was found only when Bazett's formula for correction of heart rate was applied, whereas Fridericia's formula and the nomogram method both resulted in nonsignificant changes.^[@bibr32-2042018820911803]^

As observed in some preclinical studies, QTc interval prolongation during hypoglycaemia appears to be mediated through sympathoadrenal stimulation.^[@bibr30-2042018820911803]^ It has been demonstrated that 1 week of beta-adrenergic blockade with atenolol prevented QTc interval prolongation during hypoglycaemia in healthy individuals.^[@bibr30-2042018820911803]^ This explains the large variation in QTc interval prolongation during hypoglycaemia, since the magnitude of the sympathoadrenal response during hypoglycaemia depends on several factors ([Table 2](#table2-2042018820911803){ref-type="table"}). It is well-established that frequent or recent exposure to hypoglycaemia blunts the sympathoadrenal response during an episode of hypoglycaemia.^[@bibr38-2042018820911803]^ Accordingly, patients with type 1 diabetes exhibit a reduced release of catecholamines and a reduced prolongation of QTc interval during hypoglycaemia compared with healthy subjects, and this trend is amplified by disease duration.^[@bibr25-2042018820911803],[@bibr29-2042018820911803]^ Additionally, the development of cardiac autonomic neuropathy has been shown to reduce the QTc interval prolongation during hypoglycaemia.^[@bibr31-2042018820911803]^ Taken together, these results indicate that the largest QTc interval prolongations during a spontaneous episode of insulin-induced hypoglycaemia might be found in relatively young patients with short diabetes duration.

###### 

Factors modifying QTc prolongation during hypoglycaemia in clinical studies.

![](10.1177_2042018820911803-table2)

  ---------------------------------------------- ---------------------------------------------------------------------------------
  Factors decreasing QTc interval prolongation   Beta-blockade\
                                                 Antecedent hypoglycaemia\
                                                 Diabetes duration (T1D)\
                                                 Cardiac autonomic neuropathy

  Factors increasing QTc interval prolongation   Time in hypoglycaemia\
                                                 Rate of plasma glucose decline (affects the onset of QTc interval prolongation)
  ---------------------------------------------- ---------------------------------------------------------------------------------

T1D, type 1 diabetes; QTc, corrected QT interval.

Time spent in hypoglycaemia may also play an important role in the extent of QTc interval prolongation. In one study, a progressive prolongation of QTc interval was observed, when plasma glucose was kept at a stable level of \<3.0 mmol/l in 80 min, indicating an increased risk of cardiac arrhythmias during prolonged periods of hypoglycaemia.^[@bibr29-2042018820911803]^ Furthermore, one study has suggested that the rate of decline in plasma glucose might affect the time of onset of QTc interval prolongation.^[@bibr26-2042018820911803]^ In the latter study, an intravenous bolus of insulin resulted in a rapid decline in plasma glucose and a significant QTc prolongation at a plasma glucose level of 7.2 mmol/l. While these results have not yet been reproduced, it indicates a role for poor glycaemic control with large and rapid glycaemic fluctuations in QTc prolongations.

In addition to changes in QTc interval, several other electrocardiographic changes occur during hypoglycaemia, including increased QT dispersion and changes to T-wave morphology.^[@bibr24-2042018820911803],[@bibr28-2042018820911803]^ Although these measures of cardiac repolarization have attracted less attention than the QTc interval, these findings add to the concept of an abnormal cardiac repolarization during hypoglycaemia. Another consistent finding during experimental hypoglycaemia is a significant reduction in plasma potassium, which is known to potentially induce QTc prolongations.^[@bibr23-2042018820911803],[@bibr24-2042018820911803],[@bibr28-2042018820911803],[@bibr30-2042018820911803],[@bibr31-2042018820911803],[@bibr39-2042018820911803]^ However, in a study including patients with type 2 diabetes, changes in plasma potassium was found not to correlate with QTc prolongation, and, whereas increases in QTc dispersion were prevented by a potassium infusion in a study including healthy individuals, QTc interval remained unaffected.^[@bibr24-2042018820911803],[@bibr30-2042018820911803]^

The studies described above all utilized intravenously administrated insulin. The findings have been reproduced in a study aiming to mimic a spontaneous episode of hypoglycaemia. An individualized subcutaneous bolus of insulin was administrated in 10 patients with type 1 diabetes, targeting a plasma glucose of 2.4 mmol/l, and significant QTc prolongations were found during hypoglycaemia compared with euglycaemia.^[@bibr33-2042018820911803]^

Spontaneous hypoglycaemia in clinical studies {#section4-2042018820911803}
---------------------------------------------

Several studies link spontaneous episodes of hypoglycaemia to cardiac arrhythmias.^[@bibr40-2042018820911803][@bibr41-2042018820911803][@bibr42-2042018820911803][@bibr43-2042018820911803][@bibr44-2042018820911803][@bibr45-2042018820911803][@bibr46-2042018820911803][@bibr47-2042018820911803]--[@bibr48-2042018820911803]^ As in studies of experimentally induced hypoglycaemia, QTc prolongation is an almost consistent finding in both patients with either type 1 and type 2 diabetes.^[@bibr40-2042018820911803][@bibr41-2042018820911803][@bibr42-2042018820911803][@bibr43-2042018820911803][@bibr44-2042018820911803]--[@bibr45-2042018820911803]^ Nevertheless, the results are conflicting, and a study by Koivikko and colleagues including patients with type 1 diabetes (*n* = 11) for overnight continuous glucose monitoring (CGM) and ECG monitoring found a significant reduction in QTc interval during hypoglycaemia.^[@bibr42-2042018820911803],[@bibr46-2042018820911803],[@bibr47-2042018820911803]^ These conflicting results may largely be explained by methodological problems. As alluded to above, several tools have been developed to correct QTc interval for differences in heart rate, and the use of Bazett's correction, which is widely used, results in greater estimates of QTc interval than the remaining methods.^[@bibr37-2042018820911803]^ Furthermore, T-wave morphology is changed markedly during hypoglycaemia, resulting in flattening of the T-wave, which complicates accurate measurement of the QTc interval. Nevertheless, Koivikko and colleagues still found significant changes in cardiac repolarisation consistent with increased risk of cardiac arrhythmias and cardiovascular mortality.^[@bibr47-2042018820911803]^

In an attempt to further link spontaneous hypoglycaemia to clinical episodes of cardiac arrhythmias under real-life circumstances, several studies employing concomitant Holter and CGM monitoring in an ambulatory setting in patients with type 1 and type 2 diabetes, respectively, have been performed.^[@bibr43-2042018820911803],[@bibr44-2042018820911803],[@bibr48-2042018820911803]^ In patients with insulin-treated type 2 diabetes (*N* = 25) undergoing 5 days of concomitant CGM and Holter monitoring, the incidence of bradycardia (defined as ⩾4 consecutive beats at \<45 bpm) was eightfold higher during nocturnal hypoglycaemia compared with euglycaemic periods.^[@bibr43-2042018820911803]^ Furthermore, a significant increase in atrial ectopic beats and ventricular premature beats were detected during nocturnal hypoglycaemia. During the day, a small, but significant, increase in ventricular premature beats was found, whereas no episodes of bradycardia were detected. The differences between daytime and nocturnal episodes have been explained by an insufficient counterregulatory response during sleep resulting in a prolonged duration of nocturnal hypoglycaemic episodes with multiple and lower nadirs.^[@bibr43-2042018820911803]^ During the nocturnal episodes of hypoglycaemia, an initial pattern of transient cardiac acceleration at plasma glucose nadir followed by an increased vagal counteraction associated with bradycardia was found. Hence, bradycardia during nocturnal hypoglycaemia may be explained by sympathetic withdrawal followed by vagal overcompensation.^[@bibr43-2042018820911803]^ A similar pattern of an initial increase in heart rate followed by vagal reactivation and a decline in heart rate was subsequently reproduced in patients with type 2 diabetes during a hypoglycaemic clamp.^[@bibr28-2042018820911803]^ Interestingly, healthy control participants demonstrated continued vagal withdrawal throughout the hypoglycaemic period.

In a study involving 4 days of concomitant CGM and Holter monitoring in patients with type 1 diabetes (*N* = 37), a sixfold increase in risk of bradycardia during nocturnal hypoglycaemia was found when compared with nocturnal euglycaemia.^[@bibr44-2042018820911803]^ Furthermore, atrial ectopics were more frequent during daytime hypoglycaemia when compared with daytime euglycemia. However, a subsequent analysis of data from this study has shown that the increase in bradycardia during nocturnal hypoglycaemia was driven primarily by a single participant with a markedly higher number of bradycardia beats per hour than the remaining study participants.^[@bibr44-2042018820911803]^ Accordingly, no increased risk of bradycardia during hypoglycaemia was found when this specific participant was removed from the analysis.^[@bibr49-2042018820911803]^ This led the authors to conclude that increased risk of bradycardia may apply only to certain individuals highly susceptible to bradycardia.

In another study, patients with type 2 diabetes (*N* = 94) and established cardiovascular disease underwent 5 days of concomitant CGM and Holter monitoring. It was found that patients experiencing episodes of hypoglycaemia had a significantly higher number of ventricular tachycardias.^[@bibr48-2042018820911803]^ Whereas the study did not investigate the time relation between episodes of hypoglycaemia and initiation of cardiac arrhythmias, duration of hypoglycaemia was found to be an independent risk factor of ventricular tachycardia. Although the latter study has some obvious methodological limitations since it did not investigate the time-relation between hypoglycaemic episodes and arrhythmic events, the hypoglycaemia group and the no-hypoglycaemia group were similar in age, diabetes duration, diabetic complications, diabetes treatment and prevalence of cardiovascular disease. This indicates that hypoglycaemia is not only a marker of vulnerability to cardiac arrhythmias.

Discussion {#section5-2042018820911803}
==========

Although considerable advances in the treatment of diabetes have been made during recent years including more stable insulins analogues, insulin pumps and CGM monitoring, hypoglycaemia remains an inevitable risk in patients with insulin-treated diabetes.^[@bibr50-2042018820911803]^ Presumably, only a small proportion of patients with diabetes are likely to develop clinically significant, potentially fatal cardiac arrhythmias during hypoglycaemic conditions, and these patients are difficult to identify.^[@bibr49-2042018820911803]^ Multiple factors may affect the individual risk of developing cardiac arrhythmias in relation to an episode of hypoglycaemia. Genetic factors affecting the function of cardiac ion channels and cardiac fibrosis have been suggested as an underlying predisposing factor.^[@bibr51-2042018820911803]^ Furthermore, in patients with type 2 diabetes or longstanding type 1 diabetes and established cardiovascular disease, functional and structural remodelling resulting in an ischaemic substrate to ventricular tachycardias may also be an important factor.

At least during daytime, a maintained counterregulatory response during hypoglycaemia with a large sympathoadrenal response appears to be an essential factor to the electrocardiographic changes found in clinical studies ([Figure 2](#fig2-2042018820911803){ref-type="fig"}).^[@bibr25-2042018820911803],[@bibr29-2042018820911803]^ Hence, theoretically, daytime cardiac arrhythmias are most likely to occur in patients not frequently exposed to hypoglycaemia who are experiencing an episode of severe hypoglycaemia, such as young, newly diagnosed patients with type 1 diabetes. Interestingly, in a *post hoc* analysis of data from the ACCORD study, the cardiovascular event rate was significantly lower in patients treated with beta-blockers in the intensive treatment arm compared with patients treated with beta-blockers and receiving standard therapy.^[@bibr52-2042018820911803]^ Furthermore, in patients receiving beta-blockers, no difference in all-cause mortality was found between the intensively treated arm and the standard therapy arm. While these findings indicate that beta-blockers may counteract the deleterious effects of hypoglycaemia, the use of betablockers itself may dampen early symptoms of hypoglycaemia and thereby promote hypoglycaemia. In another *post hoc* analysis of the ACCORD study, the use of beta-blockers was found to increase the incidence of severe hypoglycaemia and increase the risk of cardiovascular events.^[@bibr53-2042018820911803]^ Hence, the cardiovascular effect of beta-blockers in patients with diabetes is ambiguous, and randomized, controlled trials are needed.

![Proposed mechanism for hypoglycaemia-induced cardiac arrhythmias. Sympathoadrenal activity and parasympathetic activity is depicted with red arrows and blue arrows, respectively. When awake, a marked increase in catecholamines during episodes of hypoglycaemia results in an increase in heart rate and QTc, which is a well-stablished risk factor of ventricular arrhythmias. At night, the sympathoadrenal response is blunted and QTc prolongations less pronounced. The initial sympathoadrenal response is followed by increased vagal activity resulting in bradycardia. Preclinical studies have indicated that bradycardia may be the initial step leading to high-grade AV-block and cardiac arrest during severe hypoglycaemia.\
AV block, atrioventricular block; PSNS, parasympathetic nervous system; QTc, corrected QT interval; SNS, sympathetic nervous system.](10.1177_2042018820911803-fig2){#fig2-2042018820911803}

Whereas sympathoadrenal activation traditionally have been suspected to be the key mediator of hypoglycaemia-induced cardiac arrhythmias, several studies suggest that the parasympathetic nervous system may be responsible for nocturnal brady-arrhythmias.^[@bibr22-2042018820911803],[@bibr28-2042018820911803],[@bibr43-2042018820911803],[@bibr44-2042018820911803]^ These studies indicate two completely different mechanisms for the development of cardiac arrhythmias during the day and at night. A relatively blunted sympathetic response during prolonged episodes of hypoglycaemia may lead to sympathoadrenal exhaustion and an over compensatory parasympathetic stimulation, and eventually a cascade of bradyarrhythmias and cardiac arrest as seen in preclinical studies. Nevertheless, it should be recognized that a large gap exists between the increased risk of bradycardia during nocturnal hypoglycaemia found in observational real-life studies, and the fatal bradyarrhythmias observed during very severe hypoglycaemia in a rodent model.

Although a considerable amount of evidence supports the view that hypoglycaemia may induce cardiac arrhythmias in patients with diabetes, a direct causal link between hypoglycaemia and clinically relevant cardiac arrhythmias requiring intervention has not yet been demonstrated. Since prospective randomized trials would be unethical, future research should focus on establishing whether such a link exists by employing an observational design and taking advantage of modern tools for long-term, real-life monitoring. Additionally, further research is needed to delineate the role of the autonomic nervous system and catecholamines as mediators of hypoglycaemia-induced cardiac arrhythmia.
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